Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  therapeutic tumor infiltrating lymphocytes
Find trials that include:  Any drugs shown
Results 1-9 of 9 for your search:
Start Over
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients with Stage III or Metastatic Melanoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 14 and over
Trial IDs: 2009-0471, NCI-2014-02655, NCT01740557
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose Aldesleukin in Treating Patients With Metastatic Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC #16992, NCI-2012-01379, NCT01659151
Tumor-Infiltrating Lymphocytes after Combination Chemotherapy in Treating Patients with Metastatic Melanoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2643.00, NCI-2013-00486, NCT01807182
Combination Chemotherapy and Tumor Infiltrating Lymphocytes with or without High Dose Aldesleukin in Treating Patients with Metastatic Ocular Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: 13-C-0093, NCI-2013-01586, 130093, P131209, NCT01814046
Tadalafil and Lenalidomide with or without Activated Marrow Infiltrating Lymphocytes in Treating Patients with High-Risk Multiple Myeloma Undergoing Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 80
Trial IDs: J1343, NCI-2013-01767, NA_00084466, NA_00084466 / CIR00005616, NCT01858558
Tumor Infiltrating Lymphocytes, Aldesleukin, Chemotherapy, and Pembrolizumab in Treating Patients with Metastatic Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 66
Trial IDs: 14-C-0022, NCI-2014-02337, P131421, NCT01993719
Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients with Metastatic Melanoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0922, NCI-2015-01395, NCT02500576
Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-18377, NCI-2016-00358, NCT02652455
Start Over